Cara tries hard to spin the data, but key PhIIb pain study fails and shares slide south
Cara Therapeutics tried to spin the data in its favor, but all three doses of its lead drug CR845 flopped against a key endpoint on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
